Novartis To Increase Marketing Support As New Products Drive Growth In The Second Quarter
This article was originally published in The Pink Sheet Daily
Novartis highlights its under-appreciated new product portfolio as total sales increase by 1% in the second quarter, buffeted by adverse currency movements, generic competition to Diovan and enoxaparin, and manufacturing issues.
You may also be interested in...
The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.
A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.